Osteotech Inc.

Human bone and connective tissues for transplantation, biomaterials and implant products for musculoskeletal surgery.

Osteotech was established in 1986 and went public in 1991 (listed on the Nasdaq Stock Market® with trading symbol: OSTE). The company acquired OST Developpement SA of Clermont-Ferrand, France, in 1996.

Sam Owusu-Akyaw, President and CEO
Mark H. Burroughs, Executive VP, CFO

Kenneth P. Fallon, III, Chairman
Stephen S. Galliker
Robert W. Gunn
Robert J. Palmisano
James M. Shannon

51 James Way
Eatontown, NJ 07724
USA
Phone: +1-800-542-2045
Fax: +1-732-542-9312

Osteotech focuses on spinal, trauma and total joint revision procedures. The company provides services, and develops, markets and sells products to the orthopaedic, neurological, oral/maxillofacial and general surgery markets in the United States and Europe.

Osteotech has developed a broad range of demineralised bone grafts, registered as Grafton® product family. Structural allografts of the GRAFTECH™ familiy are made of OsteoActive™ surfaces to enable easier integration of allografts.
Osteotech processes allografts for the following applications: spinal fusions, hip and knee reconstruction, soft tissue, ligaments & tendons replacement, fractures and oncology.

Osteotech holds an extensive patent portfolio; a selection is listed below. For comprehensive information on the company’s patent portfolio please refer to the American Patent and Trademark Office or Esp@cenet.
espacenet databases